ICON Public (NASDAQ:ICLR – Get Free Report) issued an update on its FY 2024 earnings guidance on Saturday morning. The company provided earnings per share (EPS) guidance of 15.000-15.200 for the period, compared to the consensus estimate of 15.060. The company issued revenue guidance of $8.5 billion-$8.6 billion, compared to the consensus revenue estimate of $8.6 billion.
ICON Public Stock Performance
Shares of NASDAQ ICLR traded up $10.36 during midday trading on Friday, reaching $323.46. 908,602 shares of the company were exchanged, compared to its average volume of 788,375. The company has a current ratio of 1.31, a quick ratio of 1.21 and a debt-to-equity ratio of 0.36. ICON Public has a 1 year low of $221.20 and a 1 year high of $347.72. The stock has a fifty day simple moving average of $322.17 and a 200 day simple moving average of $308.87. The stock has a market cap of $26.69 billion, a P/E ratio of 39.35, a PEG ratio of 1.40 and a beta of 1.23.
ICON Public (NASDAQ:ICLR – Get Free Report) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.68 by $0.07. The firm had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.14 billion. ICON Public had a return on equity of 12.06% and a net margin of 8.57%. The business’s revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the company posted $2.96 earnings per share. On average, research analysts forecast that ICON Public will post 14.54 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Analysis on ICLR
ICON Public Company Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Stories
- Five stocks we like better than ICON Public
- Transportation Stocks Investing
- Why Call Options Volume for These 2 Stocks Spiked Together
- What Makes a Stock a Good Dividend Stock?
- MarketBeat Week in Review – 7/22 – 7/26
- Which Wall Street Analysts are the Most Accurate?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.